The genomic landscape of chronic lymphocytic leukemia: clinical implications

The genomic landscape of chronic lymphocytic leukemia: clinical implications

Interesting paper from Spain, a hot bed of CLL research, that looks at the new complexities of CLL. Clearly the days of the FISH 'buckets' are drawing to a close, as new genetic drivers are discouvered and better understood, the complexity of CLL increases.

The paper states in part....

'The German CLL Study Group has sequenced samples from a large cohort of 1,124 newly diagnosed patients to ascertain the impact of SF3B1 mutations on prognostic markers [63], whereas the CLL8 trial was interrogated for TP53, NOTCH1 and SF3B1 mutations and their relationship with treatment outcome [64].

These studies have confirmed that SF3B1 mutation correlates with adverse prognostic features, with independent prognostic value on time to treatment, and shown that mutations in NOTCH1 and TP53, but not SF3B1, associate with refractory disease.

Importantly, a randomized, prospective clinical study in the context of the British LRF CLL4 trial has independently demonstrated the prognostic value of NOTCH1 and SF3B1 mutations, which single out a new group of patients with poor outcome after treatment with chemotherapy [65].'

Full Paper:

Last edited by

1 Reply

  • Yes Chris. First the research and then the rush to make money from it.....

    See press release below..

    Adaptive Biotechnologies today announced the signing of a collaborative agreement with Bristol-Myers Squibb for the use of Adaptive's technology to discover immunological biomarkers in cancer.

    Seattle-based Adaptive Bio will use its immune profiling assay called immunoSeq to identify biomarkers that may be informative about drug response. The next-generation sequencing-based assay characterizes the repertoire of T and B cell receptors.

    The technology, Adaptive Bio said, is being applied in cancer patient cells to assess the effect of therapies on the immune system. ImmunoSeq is also being evaluated for its potential use in identifying patients who may be more likely to respond to targeted therapies based on their immune status.

You may also like...